相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
James G. Krueger et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira et al.
DRUGS (2020)
JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Janus kinases to jakinibs: from basic insights to clinical practice
Massimo Gadina et al.
RHEUMATOLOGY (2019)
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
James R. Burke et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade
Anna Schurich et al.
RHEUMATOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
Kenneth F. Baker et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
David Fiorentino et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary
Susan D. Mathias et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary
Steven R. Feldman et al.
JOURNAL OF DERMATOLOGY DERMATOLOGIC SURGERY-JDDS (2016)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
Sue J. Sohn et al.
JOURNAL OF IMMUNOLOGY (2013)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
分享论文
